Tokai Pharmaceuticals Inc
Net BuyingTKAI·US·🇺🇸 US
82%buys·18%sales
565 transactions$204.0MTotal buys·212 buys
$10.8MTotal sells·48 sells
4646 insiders
Last: Jan 13, 2025
| Date | Insider | Type | Value | |
|---|---|---|---|---|
| Jan 13, 25 | Robinson James A. Jr. | Grant | - | |
| Jan 10, 25 | Kirk Allan | Grant | - | |
| Jan 10, 25 | Kirk Allan | Grant | - | |
| Jan 10, 25 | Lee June | Grant | - | |
| Jan 10, 25 | Lee June | Grant | - | |
| Jan 10, 25 | Perrin Steven | Grant | - | |
| Jan 10, 25 | Perrin Steven | Grant | - | |
| Jan 10, 25 | Little Paul Sean | Grant | - | |
| Jan 10, 25 | Little Paul Sean | Grant | - | |
| Jan 10, 25 | Robinson James A. Jr. | Grant | - |
Tokai Pharmaceuticals Inc (TKAI) has recorded 565 insider transactions from 46 insiders. Total insider buying volume stands at $204.0M, while total selling volume is $10.8M. Overall insider sentiment is bullish (82% purchases).
Tokai Pharmaceuticals Inc (TKAI) has recorded 565 insider operations, including 212 open-market purchases ($204.0M), 48 sales ($10.8M) and 305 other operations (stock option exercises, grants, tax dispositions, donations). The insider sentiment is bullish (82% purchases).
Tokai Pharmaceuticals Inc shows moderate insider activity with 5 active months out of the last 12, typical of a company whose trading windows are concentrated around financial disclosures.
Among the most active insiders are Morrison Jodie Pope (CEO), Gros David-Alexandre C (CEO) & FLESHER GREGORY J. (CEO), with respectively 64, 18, 11 transactions.
Across all 565 recorded transactions, the breakdown by type is: buys (212, 38%), exercise (186, 33%), grant (119, 21%), sales (48, 8%).
Data sourced from regulatory filings (SEC Form 4, AMF, BaFin, FI, and other European authorities).
Tokai Pharmaceuticals Inc has recorded 565 insider operations in total, including 212 open-market purchases ($204.0M), 48 sales ($10.8M) and 305 other operations (stock option exercises, grants, tax dispositions, donations). The most recent transaction was recorded on January 13, 2025.
Insiders at Tokai Pharmaceuticals Inc are currently net buyers, with 82% purchases and 18% sales across all reported transactions. Total buy volume is $204.0M versus $10.8M in sales, indicating a bullish insider sentiment.
InsiderLens tracks 46 insiders at Tokai Pharmaceuticals Inc (TKAI). Morrison Jodie Pope (CEO, 64 tx), Gros David-Alexandre C (CEO, 18 tx), FLESHER GREGORY J. (CEO, 11 tx). Data is sourced from mandatory regulatory filings for persons with access to privileged information.
The insider signal for TKAI is bullish, based on a 82% buy ratio across 260 buy and sell transactions reported to financial regulators. Transactions from C-suite executives (CEO, CFO) and board members are generally considered the most informative signals.
Insider trading data for Tokai Pharmaceuticals Inc comes from official regulatory filings: SEC Form 4 (United States), AMF (France), BaFin (Germany), FI (Sweden), and other European financial authorities. These filings are mandatory for directors, officers, and holders of more than 10% of a company's shares. InsiderLens aggregates and normalizes this data for analysis.